Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Oncternal Therapeutics Inc (ONCT)  
$0.34 0.00 (0.00%) as of 4:30 Fri 1/5


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 49,370,000
Market Cap: 16.91(M)
Last Volume: 50,736 Avg Vol: 50,595
52 Week Range: $0.28 - $0.64
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology therapies for the treatment of cancers with critical unmet medical need. Co.'s two clinical-stage product candidates are zilovertamab and ONCT-216. Co. is developing ONCT-216, an investigational small molecule that inhibits the ETS, or E26 Transformation Specific, family of oncoproteins, which have been shown in preclinical studies to alter gene transcription and RNA processing and lead to increased cell proliferation and invasion. In addition, Co. is developing ONCT-808, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 10,980 10,980 38,980 268,980
Total Buy Value $95,117 $95,117 $104,941 $172,282
Total People Bought 2 2 3 7
Total Buy Transactions 4 4 6 14
Total Shares Sold 980 980 980 980
Total Sell Value $8,859 $8,859 $8,859 $8,859
Total People Sold 1 1 1 1
Total Sell Transactions 1 1 1 1
End Date 2024-02-08 2023-11-07 2023-05-09 2022-05-09

   
Records found: 189
  Page 2 of 8  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Leavitt Chase C. General Counsel/Secretary   •       –      –    2023-04-12 4 B $0.29 $4,350 D/D 15,000 96,901 2.66 7%     
   Yazji Salim Chief Medical Officer   •       –      –    2023-04-12 4 B $0.29 $2,850 D/D 10,000 149,676 2.66 7%     
   Krishnan Rajesh Chief Technology Officer   •       –      –    2023-01-03 4 D $1.02 $6,363 D/D (6,238) 66,754     -
   Yazji Salim Chief Medical Officer   •       –      –    2023-01-03 4 D $1.02 $10,160 D/D (9,961) 139,676     -
   Vincent Richard G Chief Financial Officer   •       –      –    2023-01-03 4 D $1.02 $4,517 D/D (4,428) 126,859     -
   Breitmeyer James B Chief Executive Officer   •       •      –    2023-01-03 4 D $1.02 $1,352 I/I (1,325) 23,918     -
   Breitmeyer James B Chief Executive Officer   •       •      –    2023-01-03 4 D $1.02 $28,349 D/D (27,793) 541,981     -
   Leavitt Chase C. General Counsel/Secretary   •       –      –    2023-01-03 4 D $1.02 $6,213 D/D (6,091) 81,901     -
   Kaufmann Gunnar F. Chief Scientific Officer   •       –      –    2023-01-03 4 D $1.02 $6,391 D/D (6,266) 66,726     -
   Breitmeyer James B Chief Executive Officer   •       •      –    2022-07-28 4 A $0.00 $0 I/I 18,750 25,243     -
   Breitmeyer James B Chief Executive Officer   •       •      –    2022-07-28 4 A $0.00 $0 D/D 185,625 569,774     -
   Leavitt Chase C. General Counsel/Secretary   •       –      –    2022-07-28 4 A $0.00 $0 D/D 43,125 87,992     -
   Kaufmann Gunnar F. Chief Scientific Officer   •       –      –    2022-07-28 4 A $0.00 $0 D/D 43,125 72,992     -
   Krishnan Rajesh Chief Technology Officer   •       –      –    2022-07-28 4 A $0.00 $0 D/D 43,125 72,992     -
   Yazji Salim Chief Medical Officer   •       –      –    2022-07-28 4 A $0.00 $0 D/D 82,500 149,637     -
   Vincent Richard G Chief Financial Officer   •       –      –    2022-07-28 4 A $0.00 $0 D/D 43,125 131,287     -
   Vincent Richard G Chief Financial Officer   •       –      –    2022-03-28 4 B $1.40 $3,500 D/D 2,500 88,162 2.66 -15%     
   Vincent Richard G Chief Financial Officer   •       –      –    2022-03-25 4 B $1.45 $3,706 D/D 2,497 85,662 2.66 -22%     
   Vincent Richard G Chief Financial Officer   •       –      –    2022-03-24 4 B $1.45 $4 D/D 3 83,165 2.66 -27%     
   Vincent Richard G Chief Financial Officer   •       –      –    2022-01-28 4 B $1.65 $4,125 D/D 2,500 83,162 2.66 -13%     
   Leavitt Chase C. General Counsel/Secretary   •       –      –    2022-01-28 4 B $1.63 $8,150 D/D 5,000 44,867 2.74 -13%     
   Breitmeyer James B Chief Executive Officer   •       •      –    2022-01-27 4 B $1.68 $42,080 I/I 25,000 46,544 2.66 -11%     
   Vincent Richard G Chief Financial Officer   •       –      –    2022-01-27 4 B $1.70 $17,500 D/D 10,000 80,662 2.74 -11%     
   Leavitt Chase C. General Counsel/Secretary   •       –      –    2022-01-27 4 B $1.78 $15,130 D/D 8,500 39,867 2.74 -11%     
   Yazji Salim Chief Medical Officer   •       –      –    2022-01-27 4 B $1.69 $16,900 D/D 10,000 67,137 2.74 -11%     
  189 Records found
  1  2  3  4  5  6  7  8   
  Page 2 of 8
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us